Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: An updated analysis in the UK

Journal of Medical Economics

Volumn 18, Issue 9, 2015, Pages 746-761

  Meier, G ^a   Gregg, M ^a   Poulsen Nautrup, B ^b  

^a GSK   (Belgium)

^b EAH   (Germany)

Author keywords

Cost effectiveness; Quadrivalent; Seasonal influenza; Trivalent; UK; Vaccination

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; FEMALE; GOVERNMENT; HOSPITALIZATION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; LIFESPAN; MAJOR CLINICAL STUDY; MIDDLE AGED; NATIONAL HEALTH SERVICE; PEER REVIEW; QUADRIVALENT INFLUENZA VACCINATION; QUALITY ADJUSTED LIFE YEAR; SEASONAL VARIATION; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; GREAT BRITAIN; INFLUENZA, HUMAN; MALE; RISK FACTOR; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; YOUNG ADULT;

EID: 84940388848     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1044456     Document Type: Article

References (54)

1. Public Health England. Influenza: the green book Chapter 19. UK; 2013. https://www.gov.uk/government/publications/influenza-the-green-bookchapter-19. Accessed 19 February 19, 2014
2. Chen R, Holmes EC. The evolutionary dynamics of human influenza B virus. J Mol Evol 2008;66:655-63
3. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8:81-8
4. World Health Organization. Influenza (Seasonal). Fact Sheet No 211. Denmark; 2014. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed April 4, 2014
5. Joint Committee on Vaccination and Immunisation. JCVI statement on the annual influenza vaccination programme-extension of the programme to children. UK; 2012. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/224775/JCVI-statement-on-the-annual-influenza-vaccination-programme-25-July-2012.pdf. Accessed February 19, 2014
6. Health Protection Agency. HPA National Influenza Annual Reports. UK; 2014. http://webarchive.nationalarchives.gov.uk/20140629102627/http://hpa. org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/EpidemiologicalData/07influsInfluenzaannualreports/. Accessed February 3, 2015
7. Fluarix Tetra Summary of Product Characteristics. UK; 2014. http://www.medicines.org.uk/emc/medicine/27537/SPC/Fluarix+Tetra/. Accessed November 3, 2014
8. GSK. GSK announces first four-strain seasonal influenza vaccine granted marketing authorisation in Germany and the UK. UK; 2013. http://www.gsk.com/en-gb/media/press-releases/2013/gsk-announces-firstfour-strain-seasonal-influenza-vaccine-granted-marketing-authorisation-ingermany-and-the-uk/. Accessed November 3, 2014
9. Peasah SK, Azziz-Baumgartner E, Breese J, et al. Influenza cost and costeffectiveness studies globally-a review. Vaccine 2013;31:5339-48
10. Meier G, Pockett RD, McEwan P, et al. Burden of influenza disease in the United Kingdom (UK): a linked General Practice Research Database (GPRD) analysis. ISPOR, 18th Annual International Meeting, New Orleans, LA, USA, 18-22 May 2013
11. Meier G, Pockett RD, McEwan P, et al. Influenza-related mortality in the United Kingdom (UK): a linked General Practice Research Database (GPRD) analysis 2001-2009. Control of Influenza VIII, Cape Town, South Africa, 5-10 September 2013
12. Matias G, Lustig R, Schuck C, et al. Model estimates of age specific influenza related mortality in the UK in recent years. Influenza Vaccines for the World (IVW 2012), Valencia, Spain, 9-12 October 2012
13. Matias G, Taylor RJ, Haguinet F, et al. Model estimates of age-specific influenza-related outpatient visits in the UK in recent years. Options for the Control of Influenza VIII, Cape Town, South Africa, 5-10 September 2013
14. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One 2014;9:e98437
15. National Institute for Health and Care Excellence. Amantadine, oseltamivir and zanamivir for the treatment of influenza. UK; 2009. http://www.nice.org.uk/guidance/ta168/resources/guidance-amantadine-oseltamivir-and-zanamivir-for-the-treatment-of-influenza-pdf. Accessed February 28,2012
16. National Institute for Health and Care Excellence. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. UK; 2008. http://www.nice.org.uk/guidance/ta158. Accessed February 28, 2012
17. National Institute for Health and Care Excellence. The guidelines manual. Assessing cost-effectiveness. UK; 2012. http://www.nice.org.uk/article/pmg6/chapter/7-assessing-cost-effectiveness. Accessed February 3, 2015
18. Health Protection Agency. HPA National Influenza Annual Reports. UK; 2011. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalI nfluenza/EpidemiologicalData/. Accessed April 19, 2011
19. Office for National Statistics (ONS). Population Estimates for UK, England and Wales, Scotland and Northern Ireland, Mid-2011 and Mid-2012. UK; 2013. http://www.ons.gov.uk/ons/publications/re-referencetables.html?edition=tcm%3A77-319259. Accessed January 20,2015
20. Office for National Statistics (ONS). Mortality Rates. UK; 2014. http://www.ons. gov.uk/ons/taxonomy/search/index.html?newquery=∗&newoffset=50& pageSize=50&nscl=Mortality+Rates&nscl-orig=Mortality+Rates&content-type=Reference+table&content-type=Dataset&sortBy=pubdate&sort Direction=DESCENDING&applyFilters=true. Accessed October 20, 2014
21. Department of Health. Seasonal flu immunisation programme 2011/2012. UK; 2011. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/216357/dh-128175.pdf. Accessed November 6, 2014
22. IBUK-eTRack no.116273. A comprehensive assessment of the full burden of influenza in the United Kingdom, 1996-2008, by age, risk status, vaccination status and influenza subtype. UK: GlaxoSmithKline, data on file, 2013
23. Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010;7:CD001269
24. Jefferson T, Di Pietrantonj C, Al-Ansary L, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010;2: CD004876
25. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and metaanalysis. BMC Med 2013;11:153
26. Tappenden P, Jackson R, Cooper K, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009;13:iii, ix-iii, 1-246
27. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003;7:iii-xiii, 1-170
28. Burch J, Paulden M, Conti S, et al. Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009;13:1-iv
29. BOI-eTrack no.116313. The burden of illness associated with influenza in the UK. UK: GlaxoSmithKline, data on file, 2013
30. Meier G, Pockett RD, McEwan P, et al. Use of antibiotics and prescription medication in influenza disease in the United Kingdom (UK). ISPOR, 16th Annual European Congress, Dublin, Ireland, 2-6 November 2013
31. Prescribing and Primary Care team Health and Social Care Information Centre. Prescription Cost and Analysis England 2013. UK; 2014. www.hscic.-gov.uk/catalogue/PUB13887/pres-cost-anal-eng-2013-rep.pdf. Accessed February 13, 2015
32. British National Formulary Vol. 67. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2014
33. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2013. UK; 2014. http://www.pssru.ac.uk/project-pages/unit-costs/2013/index.php. Accessed February 13, 2015
34. Griffin AD, Perry AS, Fleming DM. Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 2001;19:293-301
35. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997;10:1530-4
36. Meier CR, Napalkov PN, Wegmuller Y, et al. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis 2000;19:834-42
37. Department of Health. NHS charges from April 2013 announced 2014. UK; 2014. https://www.gov.uk/government/news/nhs-charges-from-april-2013-announced. Accessed November 13 2014
38. Keech M, Scott AJ, Ryan PJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998;48:85-90
39. Allsup S, Gosney M, Haycox A, et al. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess 2003;7:iii-x-1-65
40. Wolleswinkel-van den Bosch JH, Stolk EA, Francois M, et al. The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. Vaccine 2010;28(6 Suppl):G39-52
41. Office for National Statistics (ONS). Consumer Price Inflation, December 2013 (Table 9: Detailed indices annual average: 1999 to 2013). UK; 2014
42. Office for National Statistics (ONS). Average Weekly Earnings dataset 2013. UK; 2014
43. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008;26:911-24
44. Menzin J, Marton JP, Menzin JA, et al. Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation. BMC Med Res Methodol 2012;12:87
45. Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011;14:539-45
46. Rothberg MB, He S, Rose DN. Management of influenza symptoms in healthy adults. J Gen Intern Med 2003;18:808-15
47. Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med 2003;139:321-9
48. Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010;70:346-9
49. Clements KM, Meier G, McGarry LJ, et al. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother 2014;10:1171-80
50. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012;30:7443-6
51. Reed C, Meltzer MI, Finelli L, et al. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012;30:1993-8
52. Van Vlaenderen I, Van Bellinghen LA, Meier G, et al. An approximation of herd effect due to vaccinating children against seasonal influenza-a potential solution to the incorporation of indirect effects into static models. BMC Infect Dis 2013;13:25
53. Caljouw MA, Kruijdenberg SJ, de Craen AJ, et al. Clinically diagnosed infections predict disability in activities of daily living among the oldest-old in the general population: the Leiden 85-plus Study. Age Ageing 2013;42:482-8
54. Gozalo PL, Pop-Vicas A, Feng Z, et al. Effect of influenza on functional decline. J Am Geriatr Soc 2012;60:1260-7